ISPOR PUBLISHES NEW GLOBAL HEALTH CARE SYSTEMS ROAD MAP FOR DENMARK PHARMACEUTICALS

Published Jan 5, 2016
Princeton, NJ—January 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today that it has published a new Global Health Care Systems Road Map—Denmark Pharmaceuticals ISPOR Global Health Care Systems Road Maps provide an overview of country-specific, health care delivery systems. The Road Maps focus on reimbursement and pricing approval processes by country in one of three segments—pharmaceutical, medical devices, or diagnostics. ISPOR Global Health Care Systems Road Maps can benefit a variety of stakeholders—such as health care decision makers, payers, researchers, industry, clinicians, academicians, and students—who are interested in how a given country reimburses and approves pricing for health care technologies. ISPOR Global Health Care Systems Road Maps are validated by country-specific health care experts and are updated over time to reflect changes in the country’s health care delivery system. Denmark flag map According to the newly published ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals, all Danish citizens are covered by national health insurance. The Danish Medicines Agency decides the reimbursement status for pharmaceutical products and is responsible for legislation concerning pharmaceuticals, medical devices, and clinical trials. Marketing authorization in Denmark is regulated according to European Union (EU) regulation by the European Medicines Agency and does not differ in Denmark from that of other European countries. The total public health care expenditure in Denmark for 2014 were 102,569 billion Danish Krone (DKK) and pharmaceutical spending constituted 12.4% of regional health care expenses. The ISPOR Global Health Care Systems Road Map—Denmark Pharmaceuticals may be found here. Other ISPOR Global Health Care Systems Road Maps published in 2015 include: -          USA – Pharmaceuticals -          Australia – Pharmaceuticals -          Australia – Medical Devices and Diagnostics   Additional information on all of the ISPOR Tools for Health Care Decision Makers may be found here.

###

 

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×